Zhi Tong Cai Jing·2026-01-27 15:19Major Events - Guoen Technology (02768) will conduct its IPO from January 27 to January 30, with an expected listing date of February 4 [1] - Mingming Henan (01768) saw a public offering subscription rate of 1899.49 times, with a share price of HKD 236.6 [1] - Weisheng Holdings (03393) proposed a spin-off of Yuan Energy for independent listing on the Hong Kong Stock Exchange [1] - Anta Sports (02020) plans to acquire a 29.06% stake in PUMA SE for approximately EUR 1.506 billion [1] - InnoCare Pharma (03696) has reached a drug development cooperation agreement with Qilu Pharmaceutical worth over HKD 931 million, focusing on innovative therapies for cardiovascular and metabolic diseases [1] - Huajian Medical (01931) successfully developed a dual-platform solution for Nipah virus testing and upgraded its AI medical strategy [1] Financial Reports - China Merchants Securities (06099) reported a net profit attributable to shareholders of RMB 12.3 billion for 2025, an increase of 18.43% year-on-year [1] - Haitong Securities (01905) released a preliminary report for 2025, showing a profit of RMB 1.425 billion, a decrease of 5.8% year-on-year [1] - Guotai Junan Securities (02611) issued a profit warning, expecting a net profit of approximately RMB 27.533 billion to RMB 28.006 billion, an increase of 111% to 115% year-on-year [1] - Shenwan Hongyuan (06806) anticipates a net profit of RMB 9.1 billion to RMB 10.1 billion for the year, a growth of 74.64% to 93.83% [1] - Seaspan International (01308) expects a profit attributable to shareholders of approximately USD 1.2 billion to USD 1.23 billion, an increase of about 16.0% to 18.9% year-on-year [1] - Dongfang Securities (03958) forecasts a net profit of RMB 5.62 billion for 2025, an increase of 67.8% year-on-year [1] - Ganfeng Lithium (01772) issued a profit warning, expecting a net profit of RMB 1 billion to RMB 1.65 billion for 2025, turning from loss to profit [1] - CanSino Biologics (06185) anticipates a net profit of RMB 24.5 million to RMB 29 million for 2025, also turning from loss to profit [1] - China Overseas Property (02669) issued a profit warning, expecting a decline in profit attributable to shareholders of 9% to 10% year-on-year for 2025 [1] - China Traditional Chinese Medicine (00570) issued a profit warning, expecting a net loss of approximately RMB 350 million to RMB 500 million for 2025 [1] Equity and Debt Financing - China Ruyi (00136) plans to issue zero-coupon convertible bonds worth HKD 2.574 billion maturing in 2027 [2] - KANAT Optical (02276) intends to place 27 million shares at an approximate discount of 11.1%, raising about HKD 1.4 billion [2] - Hansoh Pharmaceutical (03692) proposed to issue zero-coupon convertible bonds worth HKD 4.68 billion maturing in 2033 [2] - CITIC Securities (06066) plans to issue company bonds not exceeding RMB 1.5 billion [2] - Vanke Enterprises (02202) intends to secure a loan of up to RMB 2.36 billion from its major shareholder, Shenzhen Metro Group [2]